Ausio Pharmaceuticals, LLC, is a clinical-stage biotechnology development company focused on the advancement of safe and effective medicines. Ausio’s lead product is AUS-131, a first-in-class, nonsteroidal, nonhormonal estrogen receptor β (ERβ) agonist. Ausio has successfully completed two Phase 1 trials, a Phase 2a study for menopausal symptoms and a Phase 2a for benign prostatic hyperplasia (BPH). Ausio is currently conduction clinical studies for Alzheimer’s disease patients and for women with triple negative breast cancer. . The company has garnered a strong patent position for AUS-131.
Ausio has developed AUS-131 as a pharmaceutical agent through a rigorous drug development process, as required by the US Food and Drug Administration (FDA). Ausio’s strategic goal is to collaborate with partners for AUS-131 in the United States and other markets worldwide.